Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : CardioDynamics (CDIC) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (141)	3/21/2002 1:41:35 PM
From: tuck	Respond to of 201

Nor are they going to disclose the terms of this agreement with MDT. HMMM. Maybe half the IP is all there is to it, but they could at least say something about who shoulders the costs. >>SAN DIEGO, March, 21, 2002 (PRIMEZONE) -- CardioDynamics (Nasdaq:CDIC - news), the innovator and global leader in Impedance Cardiography (ICG) technology, today announced an agreement with Medtronic, Inc., (NYSE:MDT - news), the world's leading medical technology company. The companies have signed an agreement to evaluate the clinical utility of CardioDynamics' proprietary ICG technology in optimizing the programming of Medtronic's implantable devices for Cardiac Resynchronization Therapy (CRT), and the potential integration of the BioZ(r) ICG Module with Medtronic instrumentation. During the term of the agreement, the companies agree to share ownership of unique intellectual property developed through the collaboration for biventricular pacing applications. ``It is an exciting time in healthcare when innovators of breakthrough technologies can combine talents and efforts to develop new solutions that will improve care and quality of life. This first-of-its-kind collaboration with Medtronic has the potential to change the standard of care for pacemaker patients and open yet another door for our technology's contribution to healthcare,'' stated Michael K. Perry, Chief Executive Officer of CardioDynamics. ``Through our partnership strategy, we are working with some of the best research and product development teams in the medical industry. We are very pleased to join forces with the global leader specializing in pacemaker technology to explore the use of our ICG capability with their products.'' Heart failure (HF) affects 22.5 million people worldwide. CRT is a new treatment for heart failure that uses an implantable device (biventricular pacemakers) to improve the pumping efficiency of the heart. Pacemaker programmers enable physicians to evaluate and vary pacemaker settings. Prior to BioZ ICG technology, physicians were limited to using Echocardiography (Echo) to ensure objective, optimal settings. The challenges with Echo include expense, time, and dependency on a highly trained technician. In recent studies from leading medical facilities, BioZ's ICG technology has been shown to be as effective and less costly than the widely used Echo technique in the optimization of pacemakers in heart failure and cardiac patients. ICG is valuable in pacemaker applications because it identifies pacemaker settings that produce the optimum cardiac output to meet the body's demands.<< snip Cheers, Tuck

To: tuck who wrote (141)	3/21/2002 8:06:55 PM
From: scott_jiminez	Respond to of 201

One potential/logical consequence of CDIC's problems... Message 17230291

To: tuck who wrote (141)	3/21/2002 9:37:12 PM
From: wolfdog2	Respond to of 201

Tuck, I have a good sized position in the company. I couldn't agree with you more that they should have disclosed the recall previously. Among other causes, they blamed their hardware shortfall on 9/11. Huh? That's a red flag right there. I've lost a good deal of faith in management, but I like the product and think the recall itself was a non-event. I expect the stock will be substantially higher next year, but would prefer if management were more up front about material problems.

To: tuck who wrote (141)	3/22/2002 11:21:20 AM
From: Biomaven	Read Replies (2) \| Respond to of 201

tuck, I exited my small position yesterday at the open when the stock was modestly up because of the MDT announcement, before people got a chance to digest the earnings release. I figure I'll get a chance to buy it back cheaper - the only issue is whether to wait for next quarter's results to see if this indeed was a temporary blip or not. (I'm inclined to think it was - but temporary might mean two quarters, not one, while confidence is re-established). BTW, I don't see this stock as a competitor for HDIE at all - I view the technologies as complementary, not as replacements for each other. Peter